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www.cdatm.orgAbstractObjective: To evaluate the feasibility and satefy of transcatheter aortic valve implantation in animals by using a new balloon-
expanding valved stent.
Methods: The balloon-expandable stent is made from cobalt-based alloy material and designed with a tubular, slotted structure.
Fresh bovine pericardium was treated, sutured and fixed on the balloon-expandable stent. Ten healthy sheep (five males and five
females), weighing an average of (25.16 ± 1.83) kg, were selected to undergo transcatheter implantation of the valve stents. The
function of the valve stent was evaluated by angiography, echocardiography, and histology six months after the procedure.
Results: Of the ten experimental sheep, two sheep died during the operation because the higher position of the artificial valve
affected the opening of the coronary artery. We successfully implanted the aortic valve stent in other eight sheep; however, one
sheep died of heart failure twoweeks after the operation due to the lower position of the valve stent. The valve stents were implanted
in the desired position in seven sheep. Ascending aortic angiographic and autoptic findings immediately after the operation
confirmed the satisfactory location and function of the valved stent. Echocardiography, angiography, and histology at six post-
operative months confirmed the satisfactory location and function of the valve stent.
Conclusion: We successfully implanted our new valve stent as a replacement of native aortic valve via the transcatheter route with
satisfactory outcome.
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Degenerative calcific aortic stenosis has become
one of the most common adult valvular diseases.1
Surgical aortic valve replacement is an effective
treatment for severe aortic stenosis. However, many
patients with severe aortic valve stenosis do not un-
dergo surgery because of advanced age and life-
threatening comorbidities. Since transcatheter aortic
valve implantation (TAVI) was first accomplished in
2002, TAVI has been successfully used in clinics2 and
has developed rapidly. It is gradually becoming a
substitution therapy for severe aortic stenosis in pa-
tients with high risk of surgery.3 We developed a new
balloon-expandable valve stent and delivery system. In
the present study, we evaluated the feasibility and
safety of transcatheter implantation of a new balloon-
expandable valve stent into the aortic valve position
of sheep.
Methods
Construction of a balloon-expandable valve stent
The valve stent and delivery device (Fig. 1) were
produced by LePu Medical Technology (BeiJing Co.,
Ltd, China), according to our design and instructions.
The balloon-expandable stent is made from cobalt-
based alloy material and designed with a tubular,
slotted structure. The stent was 24 mm in height, with
diameter sizes of 20, 23, and 26 mm.
The prosthetic heart valve is made from bovine
pericardium. Fresh bovine pericardium was washed
repeatedly, after removing the adipose tissue on its
surface, and it is rinsed in cold saline solution until no
blood color was found. The bovine pericardial tissueFig. 1. Valve stent and delivery system; A. Upper view of valvematerial was treated with Hank's buffer for 8e12 h and
0.6% glutaraldehyde solution for 36 h at 4C for
sterilization. After washing repeatedly with saline so-
lution, the tissue material was agitated by vibration in a
formic acid dilution solution for 1 h. Then, the valve
was placed in a mixture of 2-(N-morpholino)-acetic
acid buffer solution (20 g/L), 1-ethyl-3-(3-dimethyl
aminopropyl)-carbodimide (5.8 g/L), N-hydroxy-suc-
cinimide (0.7 g/L), and hexanediamine (7.2 g/L) at pH
5.5 for 18e24 h and stored in a glutaraldehyde solution
in the refrigerator.
The treated bovine pericardium was cut into three
leaflets, with the two ends of each leaflet overlapping.
One end of a leaflet was opposite that of another
leaflet. The two ends of each leaflet were sutured with
a 7e0 polypropylene suture material and then fixed
inside the stent, forming three leaflets. A polyester
cloth was used to cover the one-third portion of the
valve stent to reduce perivalvular leakage (Fig. 1A and
B). The valve stent was stored in 0.3% glutaraldehyde
solution. Before application, 75% alcohol was used for
disinfection and sterilization and normal saline solu-
tion was used for rinsing.
Stent delivery system
The stent delivery system is comprised of a hemo-
static loader sheath, a 20F artery sheath, an inner
dilator, and a delivery catheter (Fig. 1C). The delivery
catheter was made of polytetrafluoroethene with a
superlubricious hydrophilic coating. The design of the
deflectable forepart of the delivery catheter was made
to facilitate passage of the valve stent through the
curve of aortic arch. The function of the deflection is
accomplished by rotation of the handle of the delivery
catheter. The proximal portion of a delivery catheter isstent; B. Lateral view of valve stent; C. Delivery device.
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onto the balloon of the delivery catheter using a me-
chanical crimping device. The balloon can be inflated
to expand and release the valve stent which was used to
replace the native aortic valve. The role of the hemo-
static loader sheath is to ensure the positioning of the
delivery catheter through the hemostasis valve of the
20F artery sheath. The stent delivery system can be
classified into 20, 23, and 26 mm sizes, according to
the diameter of the balloons.
Animals
Animal studies were approved by the local hospital
ethics committee. All animals received care in
compliance with the Guide for the Care and Use of
Laboratory Animals (www.nap.edu/catalog/5140.
html). Ten healthy sheep (five males and five fe-
males) weighing 25.16 ± 1.83 kg were used. Preop-
erative electrocardiography, chest radiography, and
echocardiography (ECG) revealed no abnormality.
Anesthesia was induced in the sheep with an intra-
muscular injection of ketamine (10 mg/kg) and main-
tained with intraoperative intravenous propofol
(0.2 mg$kg1$min1). All the sheep were monitored
by performing ECG and oxygen saturation.
Valve stent implantation
The right femoral vein was punctured and we
inserted a 6F leak-proof sheath, and 50 U/kg of heparin
was administered. The temporary pacing lead was
introduced into the apex of the right ventricle via the
femoral vein sheath and then the pacemaker function
was confirmed.
The left carotid artery was exposed and a 6F leak-
proof sheath was introduced, and a 6F pigtail catheter
was introduced into the ascending aorta for contrast
medium injections. Aortic root angiography was per-
formed to determine the best imaging position and
measure the diameter of the aortic valve annulus
(Fig. 2A). The type of valve stent was selected ac-
cording to the diameter of the aortic valve annulus,
and then it was compressed to the balloon of the de-
livery catheter by using a mechanical crimping device.
The diameter of the selected valve stent should be
2e4 mm larger than the diameter of the aortic valve
annulus.
The sheep were placed in a right lateral decubitus
position. After the abdomen was opened, a 2 cm length
abdominal aorta was exposed from the retroperitoneum
and a 7F artery sheath was introduced. A stiff guidewire was advanced into the apex of the left ventricle
via the 7F sheath under fluoroscopy (Fig. 2B). After
the 7F sheath was withdrawn, a 20F artery sheath and
inner dilator were inserted into the abdominal aorta
over the stiff guide wire. Then, the inner dilator was
removed and the 20F artery sheath was left in place.
The delivery catheter equipped with the valve stent was
threaded into the stiff wire and advanced into the
descending aorta through a hemostatic loader sheath
and the 20F artery sheath. Further manipulation and
axial support with the deflection delivery catheter was
required to cross the aortic arch and the native valve
along with the stiff guide wire. When the valve stent
was placed in the native aortic valve, aortic root
angiography was performed (with 800-pis pressure and
at 15 mL/s for a total volume of 20 mL) to determine
the valve stent placement at the native aortic valve of
the sheep by adjusting the depth of the delivery
catheter.
Rapid right ventricular pacing (300 beats/min) was
used to minimize pulsatile transaortic flow. Then the
valve stent position was confirmed again using aortic
root angiography (Fig. 2C). Under fluoroscopic
guidance, the valve stent was expanded and released
by injecting the balloon with dilute (10%) contrast
agent (Fig. 2D). The contrast agent was extracted
when the valve stent was fully inflated. Temporary
pacing was stopped and the delivery catheter was
extracted. The position and function of the artificial
valve were observed by aortic root angiography
(Fig. 2E and F).
Postoperative treatment
The delivery catheter, stiff guide wire, and 20F
outer sheath were all removed. The abdominal aorta
was sutured with 6e0 polypropylene suture material
(Johnson and Johnson, New Brunswick City, NJ). The
muscle and skin were then sutured after no errhysis
was observed for three minutes. The pigtail catheter,
temporary pace lead, and sheath on the carotid artery
and femoral vein were all removed. A 7e0 poly-
propylene suture material was used for suturing the
carotid artery. A 5-min compression hemostasis was
applied at the puncture site of the femoral vein. All the
sheep received postoperative intramuscular injections
of penicillin and subcutaneous injections of heparin.
Penicillin was administered for seven days to prevent
infection, and then low-molecular-weight heparin and
aspirin were administered for three and 60 days,
respectively. The wound was disinfected daily with
iodine. Sutures were removed at 6 days.
Fig. 2. Procedure of transcatheter aortic valve implantation. A. The angiogram of ascending aorta; B. A stiff guide wire was advanced into the
apex of the left ventricle; C. Valve stent was placed in the native aortic valve; D. Valve stent was expanded and released by injecting the balloon
with dilute contrast agent; E and F. The position and function of the artificial valve were observed on angiography after implantation.
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The location and function of the artificial aortic valve
were detected by aortic root angiography immediately
after the operation. One randomly selected sheep was
euthanized two hours after successful implantation for
macroscopic inspection at necropsy. The general health
status, including eating, defecation, and activity of the
sheep were observed after the operation. The perfor-
mance of the prosthetic aortic valve, including peri-
valvular leakage and aortic regurgitation, was evaluated
based on findings from transthoracic echocardiography
angiography six months after the operation. In addition,
the function of the heart and hemodynamics of the
artificial valve were observed. The prosthetic valve was
examined macroscopically and histologically at six
months after the operation.
Statistical analysis
Statistical analysis of all the data was performed by
using SPSS 18.0 software (SPSS Inc., IL, USA).
Measurement data were expressed as mean ± standard
deviation (SD).Results
Operation results
Two sheep (No. 1 and No. 3) died of ventricular
fibrillation during the operation because the higher
position of the artificial valve affected the opening of
the coronary artery. The valve stent implantation was
completed in eight sheep. One sheep (No. 2) died of
heart failure two weeks after the operation due to
serious paravalvular leakage induced by the lower
position of the valve stent. Autopsy showed that the
valve stent was located under the aortic valve leading
to serious paravalvular leakage. One sheep (No. 6) was
sacrificed 2 h after successful implantation to observe
the position and function of the valve. The cardiac
anatomy of the sacrificed animal showed that the valve
stent was well “anchored” against the aortic wall with
an optimal position, the native aortic valves were stuck
between the annulus and stent, no obstruction of cor-
onary artery origins was observed, the lower edge of
the valve stent was far away from the mitral valve, no
tears of the prosthetic valve leaflets were apparent
(Fig. 3).
Fig. 3. Cardiac anatomy of sacrificed animal; A. Valve stent was well “anchored” against the aortic wall with optimal position; B. coronary artery
origins and mitral valve were not affected.
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the remaining six sheep, no complications related to the
operation occurred. Temporal sinus tachycardia
occurred during implantation of the stent. No AV block
was detected. The aortic root angiography revealed that
the valve stent was implanted at a correct position and
the switch function of the prosthetic aortic valve was
normal, without significant regurgitation (Fig. 2E). The
aortic annulus diameter was 21.88± 1.43 mm, the mean
valve stent diameter of 24.5 ± 1.58 mm, the operation
time was 104.30 ± 12.07 minutes, and the radiographic
fluoroscopy time was 9.40 ± 2.41 minutes.
Results at six postoperative months
The six sheep survived for more than six months
with normal diet and activity. Transthoracic color
Doppler ultrasound at six postoperative months
showed the normal position of the prosthetic valve and
function of the artificial valve without obvious stenosisFig. 4. Ultrasound at 6 months postoperative; A. Valve stent was located
found.or insufficiency. The aortic valve stent did not affect
the function of the mitral valve and its normal activities
(Fig. 4). Angiography at six postoperative months
revealed that the stent was at its location with full
spread, without deformation and fracture, and that the
artificial aortic valve had no regurgitation. The left and
right coronary artery openings were not affected by the
artificial aortic valve (Fig. 5). The H&E staining of the
artificial valve leaflets at six postoperative months
showed that the surface of the leaflet was smooth,
without obvious cell or tissue infiltration (Fig. 6).
Discussion
Recently, TAVI technology has developed rapidly
and has been widely applied in the clinics. More than
100000 patients have received the TAVI treatment.
TAVI is recommended as an alternative treatment
method for severe stenosis in patients with a high risk
of surgical operation.4,5in the aortic valve. B. No regurgitation or paravalvular leakage was
Fig. 5. Angiography at 6 postoperative months showed artificial aortic valve had no regurgitation.
Fig. 6. Histological images of the artificial valve leaflets at 6 post-
operative months showed the surface of the leaflet was smooth,
without obvious cell or tissue infiltration.
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Cobalt-based alloy has good physicochemical
properties, which allows it to be widely applied in
medical and biological fields. First, the material shows
good biocompatibility, no irritation to the recipient's
body, which has been observed. Second, the material
has a stable chemical performance and strong corro-
sion resistance. Third, it shows good mechanical
properties with anti-fraying and fatigue resistance.
Moreover, it has a low specific gravity and light quality
for easy crimping and transportation.
Bovine pericardium as a biological valve has been
applied in cardiac surgery. After treatment, the bovine
pericardium shows good toughness and fatigue resis-
tance performance, making it an ideal material for
making artificial valves. Its surface performance is
improved after sterilization, decellularized treatment,
and calcification resistance. The polyester cloth that
covers the dense stitching around the one-thirdsegment of the stent was used as a gland pouch and
effectively reduced the perivalvular leakage.
The artery sheath and delivery catheter are made of
polytetrafluoroethylene with a hydrophilic coating. The
myocardial and vascular smooth muscle are not easily
damaged because of their smooth surface. The valve
stent and ascending aorta should maintain a coaxial
orientation during the stent implantation. The delivery
catheter is characterized by the ability of its deflectable
forepart; the function of deflection is accomplished by
the rotation of the handle of the delivery catheter. This
function made it easy for the stent to pass through the
aortic arch and maintain the coaxial orientation with
the ascending aorta, which is conducive to a steady
release of the stent.
Implantation access
TAVI with transfemoral access is often preferred
due to a perception of it being less invasive in an adult.
However, the diameter of the femoral artery of adult
sheep is only 4mme5 mm which allows, at most, a 14F
sheath to be inserted. The diameter of the abdominal
aorta of an adult sheep is 7mme8 mm which is rela-
tively close to the average diameter of the femoral
artery of adult humans. So the approach via the
abdominal aorta was selected for transcatheter im-
plantation of the valve stent in this animal study. The
blood flow of the abdominal aorta would be completely
blocked by a 20F artery sheath during a TAVI proce-
dure via the abdominal aorta. Furthermore, It takes
time to suture the puncture site of the abdominal aorta
after the procedure. So we need to shorten the oper-
ating time, otherwise, avascular necrosis of both lower
limbs may occur.
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The key factor of successful TAVI is to achieve an
accurate position of the valve stent. The opening of the
coronary artery is affected by the higher location of the
stent, which might have led to myocardial infarction;
whereas serious paravalvular leakage occurred as a
result of the lower positioning of the artificial valve,
which might have led to heart failure. Several points
should be considered to accurately position the artificial
valve, including the following: 1) The best angiography
posture. The three aortic sinuses of sheep should be in
the same line under angiography; which is necessary for
accurate location of the valve stent. In the TAVI opera-
tion, the sheep was placed in a right lateral decubitus
position, the posteroanterior position and a 5e10 cra-
nio view were used in our study. The optimal angiog-
raphy position was determined by performing
angiography, with the aortic sinus in a straight line as the
principle reference. 2) Rapid cardiac pacing. The aortic
annulus is moving up and down too much within a
normal heartbeat. Stent positioning at this time could not
be accurate. High left ventricular pressure was produced
by the great amount of the left ventricular blood flow due
to the aortic valve orifice being clogged by the balloon of
the expandable stent, which could lead to the balloon
being “washed away”. Rapid ventricular temporary
pacing can slow down the velocity of blood flow from
the left ventricle and reduce the motion amplitude of the
aortic annulus.6 The heart rate of the sheep is between
130 and 180 beats/min. Our experiment found that aortic
pressure was significantly reduced by 250e300 beats/
min of rapid pacing. The stent was released when the
aortic pressurewas decreased significantly, as confirmed
by performing pressure monitoring after rapid tempo-
rary pacing. 3) Stent size. The diameter of the stent used
was 2e4 mm larger than the diameter of the aortic
annulus, in accordance with the principle of stent se-
lection. Then if the valve stent achieved good expansion,
it would closely adhere to the aortic annulus. 4) Stent
releasing position. The artificial valvewas sutured to the
lower one-third segment of the stent. The accurate
release position to cover the animal's native valve was at
the lower one-third segment. That is, the lower edge of
the stent was below the sinus; the distance from the
lower edge to the sinus was 3e5 mm.
Valve function
Angiography and ultrasound observations at six
postoperative months preliminarily indicated good
performance of the artificial valve. A color Dopplerultrasound image confirmed the artificial valve with
good open-and-close function, without significant ste-
nosis or regurgitation. The hemodynamics examination
indicated that the differential pressure across the arti-
ficial aortic valve was normal. All the results at six
postoperative months indicated that the artificial valve
could replace the native valve with good performance.
Complications
This study showed a high incidence of malposi-
tioning of the valve stent compared with TAVI in aortic
stenosis. Unlike calcific aortic stenosis, the normal
aortic valve of sheep lacks fixation at the annulus
during deployment, resulting in malpositioning. If the
valve stent system is used to treat aortic stenosis, the
incidence of malpositioning complications may be
reduced. With TAVI in calcific aortic stenosis, peri-
valvular leak is noted in nearly all patients.7 The
reason is the poor coaptation between the stent and
irregular calcium annulus which provides points for
blood to leak back across the annulus into the ventricle.
In this study, the valve stent were implanted in an
optimal position and closely adheres to the smooth
aortic wall in the normal aortic valve of the sheep.
Additionally, the polyethylene terephthalate fabric
covered portion of the stent can prevent blood from
flowing back into the left ventricle. So little regurgi-
tation or paravalvular leakage was observed in our
experiment. Cobalt-based alloy materials were char-
acterized by high hardness and high resistance to
abrasion. No stent deformation or migration was seen
in any of the animals at six months after implantation.
Study limitation
This study had several limitations. First, the number
of animals was small and the follow-up time was short.
Second, the TAVI was performed in healthy animals
with normal aortic valves.Disclosures
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